Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IRMD

IRMD - iRadimed Corp Stock Price, Fair Value and News

43.17USD-0.25 (-0.58%)Market Closed

Market Summary

IRMD
USD43.17-0.25
Market Closed
-0.58%

IRMD Stock Price

View Fullscreen

IRMD RSI Chart

IRMD Valuation

Market Cap

546.7M

Price/Earnings (Trailing)

30.5

Price/Sales (Trailing)

8.08

EV/EBITDA

21.4

Price/Free Cashflow

48.01

IRMD Price/Sales (Trailing)

IRMD Profitability

Operating Margin

76.57%

EBT Margin

33.44%

Return on Equity

23.55%

Return on Assets

20.36%

Free Cashflow Yield

2.08%

IRMD Fundamentals

IRMD Revenue

Revenue (TTM)

67.7M

Rev. Growth (Yr)

13.72%

Rev. Growth (Qtr)

0.84%

IRMD Earnings

Earnings (TTM)

17.9M

Earnings Growth (Yr)

21.45%

Earnings Growth (Qtr)

-8.88%

Breaking Down IRMD Revenue

Last 7 days

1.6%

Last 30 days

2.4%

Last 90 days

-2.5%

Trailing 12 Months

-13.8%

How does IRMD drawdown profile look like?

IRMD Financial Health

Current Ratio

9.44

IRMD Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202467.7M000
202356.5M59.9M63.0M65.6M
202244.9M47.8M50.3M53.3M
202132.3M35.3M38.5M41.8M
202038.8M36.3M34.1M31.7M
201931.8M33.6M36.0M38.5M
201825.0M26.9M28.8M30.4M
201728.7M24.4M22.4M23.1M
201633.6M35.8M35.3M32.5M
201519.1M22.0M26.4M31.6M
201412.4M13.5M14.6M15.7M
201300011.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of iRadimed Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
allen monty k
sold
-84,432
43.3654
-1,947
-
Dec 27, 2023
susi roger e.
sold
-232,547
46.5094
-5,000
ceo, president, chairman
Dec 26, 2023
susi roger e.
sold
-230,000
46.00
-5,000
ceo, president, chairman
Dec 21, 2023
susi roger e.
gifted
-
-
-300,000
ceo, president, chairman
Dec 19, 2023
susi roger e.
sold
-225,696
45.1393
-5,000
ceo, president, chairman
Dec 18, 2023
susi roger e.
sold
-220,402
44.0805
-5,000
ceo, president, chairman
Dec 14, 2023
hawkins james b
acquired
42,085
9.84
4,277
-
Dec 14, 2023
hawkins james b
sold
-190,687
44.5843
-4,277
-
Dec 13, 2023
hawkins james b
acquired
51,355
9.84
5,219
-
Dec 13, 2023
hawkins james b
sold
-223,540
42.8319
-5,219
-

1–10 of 50

Which funds bought or sold IRMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
CIM, LLC
added
0.74
23,508
419,129
0.06%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
1.96
-20,790
356,407
-%
May 16, 2024
COMERICA BANK
added
2,151
60,352
63,390
-%
May 15, 2024
Tudor Investment Corp Et Al
sold off
-100
-330,534
-
-%
May 15, 2024
Man Group plc
reduced
-77.37
-944,490
250,567
-%
May 15, 2024
Aristides Capital LLC
added
87.11
343,956
812,627
0.30%
May 15, 2024
Squarepoint Ops LLC
new
-
547,763
547,763
-%
May 15, 2024
FAIRFIELD, BUSH & CO.
sold off
-100
-1,567
-
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
sold off
-100
-221,542
-
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
added
6.06
-24,174
1,385,680
-%

1–10 of 46

Are Funds Buying or Selling IRMD?

Are funds buying IRMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IRMD
No. of Funds

Unveiling iRadimed Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
susi roger e.
36.4%
4,587,950
SC 13G/A
Feb 12, 2024
nine ten capital management llc
6.3%
799,366
SC 13G/A
Feb 09, 2024
blackrock inc.
5.2%
651,948
SC 13G
Feb 02, 2024
soleus capital master fund, l.p.
5.1%
641,706
SC 13G/A
Feb 14, 2023
soleus capital master fund, l.p.
5.9%
742,004
SC 13G/A
Feb 13, 2023
renaissance technologies llc
4.73%
594,312
SC 13G/A
Feb 10, 2023
nine ten capital management llc
6.2%
781,766
SC 13G/A
Sep 01, 2022
soleus capital master fund, l.p.
5.1%
646,411
SC 13G
Feb 11, 2022
renaissance technologies llc
5.62%
693,312
SC 13G/A
Feb 09, 2022
nine ten capital management llc
5.9%
730,659
SC 13G/A

Recent SEC filings of iRadimed Corp

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
Jun 04, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report
Jun 03, 2024
144
Notice of Insider Sale Intent
May 09, 2024
ARS
ARS
May 08, 2024
EFFECT
EFFECT
May 06, 2024
S-3/A
S-3/A
May 06, 2024
CORRESP
CORRESP
May 03, 2024
DEFA14A
DEFA14A
May 02, 2024
8-K
Current Report

Peers (Alternatives to iRadimed Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
40.3B
-0.87% -1.28%
32.05
4.47
-2.84% -3.00%
67.6B
19.7B
-1.49% -8.74%
50.68
3.43
4.82% -17.56%
19.3B
3.9B
-8.68% -23.17%
41.69
4.92
5.72% 46.72%
17.2B
14.9B
-4.71% -24.07%
6.49
1.16
2.98% 207.68%
MID-CAP
9.6B
3.5B
-1.72% 24.73%
30.66
2.71
6.16% 35.06%
8.4B
12.4B
-11.97% -13.19%
21.71
0.68
-0.93% -18.83%
8.1B
2.6B
-6.15% -25.48%
-24.99
3.09
-6.25% -68.58%
5.4B
3.9B
-7.61% -31.99%
-56.77
1.38
0.23% 90.80%
3.4B
387.1M
-0.71% 28.31%
-215.21
8.86
30.82% 65.57%
2.0B
6.6B
-12.43% -18.98%
10.47
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
15.14% 13.53%
-2.17
0.46
7.94% -1695.32%
390.3M
169.3M
0.92% -1.83%
-5.08
2.31
7.49% -244.90%
246.7M
324.0M
-3.14% -43.23%
-1.28
0.76
-3.19% -337.41%
50.2M
50.5M
2.84% -79.14%
-2.2
1
14.25% -10.06%
1.8M
3.7M
75.00% -80.56%
-0.15
0.49
5.77% 8.23%

iRadimed Corp News

Latest updates
Yahoo Sport Australia12 Jun 202404:36 pm
MarketBeat03 Jun 202407:00 am
Yahoo Canada Shine On29 May 202407:00 am
Seeking Alpha04 May 202407:00 am

iRadimed Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue0.8%17,59817,45216,50516,13015,47514,86413,40712,72212,31111,87310,9079,8109,2248,5467,6996,7958,67810,8919,9639,2268,438
Cost Of Revenue4.2%4,2104,0393,6673,9443,7543,6432,8652,5822,9312,6232,5022,4782,1622,1071,9581,8652,2142,7422,1681,8582,048
Gross Profit-0.2%13,38813,41312,83712,18611,72111,22010,54310,1409,3809,2508,4067,3327,0626,4395,7414,9306,4648,1497,7957,3676,390
Operating Expenses4.7%8,6398,2536,9327,2237,7146,9676,4105,9736,3056,1405,3195,4885,2855,7884,9567,8595,7275,9105,2764,9924,876
  S&GA Expenses-81.5%8214,4322,8642,9487943,6653,0372,9083,0703,1212,5862,4702,3793,0692,2822,3742,4342,5622,2972,2002,111
  R&D Expenses945.4%3,827-4524539623,000605492663519495481454476513477483430379370331353
EBITDA Margin0.9%0.35*0.34*0.33*0.31*0.32*0.32*0.32*0.32*0.28*0.27*0.23*0.18*---------
Income Taxes-3.1%1,1071,1421,3411,1199441,030810939573-77951838838427.00-280-798-933-887174365-239
Earnings Before Taxes-7.7%5,2445,6826,4095,2984,3504,7044,2374,1803,0603,1133,0941,8571,771665794-2,9118362,3542,6292,4541,606
EBT Margin0.8%0.33*0.33*0.33*0.31*0.31*0.30*0.29*0.28*0.25*0.24*0.19*0.14*---------
Net Income-8.9%4,1374,5405,0674,1803,4063,6743,4273,2412,4873,8932,5761,4701,3876371,075-2,1121,7693,2422,4552,0891,846
Net Income Margin1.0%0.26*0.26*0.26*0.25*0.24*0.24*0.26*0.26*0.23*0.22*0.16*0.13*---------
Free Cashflow6.9%3,6133,3811,0853,309-1,7492,7813,7461,4511,2433,2753,2283,462---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-4.5%88.0092.0087.0081.0076.0086.0080.0076.0072.0083.0078.0076.0072.0071.0070.0069.0068.0067.0063.0057.0054.00
  Current Assets-5.4%72.0076.0072.0066.0061.0077.0072.0068.0066.0076.0072.0069.0065.0064.0063.0060.0061.0059.0056.0050.0047.00
    Cash Equivalents-9.3%45.0050.0047.0046.0043.0058.0056.0052.0050.0062.0058.0055.0051.0050.0048.0045.0045.0043.0039.0032.0030.00
  Inventory-1.0%13.0013.0012.008.006.005.005.005.004.004.004.004.005.004.005.005.004.004.004.004.004.00
  Net PPE1.8%9.009.009.009.009.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.00
Liabilities-42.6%12.0021.0013.0012.0011.0012.0010.0010.0010.0011.0011.0011.009.0010.0010.0010.0010.0011.0011.0010.0010.00
  Current Liabilities-53.4%8.0016.008.008.007.009.006.006.006.007.006.006.005.005.005.005.005.006.006.005.005.00
Shareholder's Equity6.6%76.0071.0075.0069.0064.0074.0070.0066.0063.0072.0068.0065.0063.0061.0061.0058.0058.0056.0052.0047.0045.00
  Retained Earnings9.6%47.0043.0047.0042.0037.0047.0044.0040.0037.0047.0043.0041.0039.0038.0037.0036.0038.0036.0033.0031.0029.00
  Additional Paid-In Capital2.0%29.0028.0028.0027.0027.0026.0026.0026.0026.0025.0025.0024.0024.0024.0024.0022.0020.0019.0019.0017.0016.00
Shares Outstanding0.0%13.0013.0013.0013.0013.0013.0013.0013.0013.0012.0012.0012.00---------
Float----379---242---185---146---107-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-0.7%3,8833,9121,3933,5144,6463,0393,9381,6391,4263,3663,3783,5719432,4961,3347911,1973,9493,1382,480665
  Share Based Compensation14.1%629551534568534427393121453392777-57.563483184172,659569549456468382
Cashflow From Investing24.3%-478-632-439-378-6,557-471-55678.00-424260-220783-173301-110287-2309351,369339557
Cashflow From Financing-2961.8%-8,039-262-31.37-89.77-13,272-19852.00-5.72-12,5542.0054.004.00-36.25-277868-256188-39.951,708-82.20434
  Dividend Payments-7,976---13,223---12,559------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IRMD Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME  
Revenue$ 17,598,119$ 15,475,083
Cost of revenue4,210,3963,753,635
Gross profit13,387,72311,721,448
Operating expenses:  
General and administrative3,991,2113,920,510
Research and development3,827,1652,999,976
Sales and marketing821,000793,716
Total operating expenses8,639,3767,714,202
Income from operations4,748,3474,007,245
Other income, net495,154342,409
Income before provision for income taxes5,243,5014,349,655
Provision for income tax expense1,106,968943,589
Net income$ 4,136,533$ 3,406,066
Net income per share:  
Basic (in dollars per share)$ 0.33$ 0.27
Diluted (in dollars per share)$ 0.32$ 0.27
Weighted average shares outstanding:  
Basic (in shares)12,662,52612,593,033
Diluted (in shares)12,749,97312,686,699

IRMD Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 45,126,676$ 49,762,198
Accounts receivable, net of allowance for credit losses of $330,628 as of March 31, 2024, and $368,835 as of December 31, 202313,026,80212,224,273
Inventory, net12,696,16012,821,194
Prepaid expenses and other current assets1,035,9641,193,447
Total current assets71,885,60276,001,112
Property and equipment, net9,451,9039,288,625
Intangible assets, net2,669,8582,519,053
Operating lease right-of-use asset1,938,4272,043,043
Deferred tax asset, net1,883,6892,122,816
Other assets184,701181,449
Total assets88,014,18092,156,098
Current liabilities:  
Accounts payable1,285,3661,857,091
Accrued payroll and benefits2,144,2212,775,103
Other accrued taxes136,538103,241
Warranty reserve115,030117,463
Deferred revenue2,338,4142,570,407
Dividend payable 7,975,997
Current portion of operating lease liabilities418,814427,963
Other current liabilities250,000250,000
Accrued income taxes928,287250,041
Total current liabilities7,616,67016,327,306
Deferred revenue, non-current2,756,4352,793,548
Operating lease liabilities, non-current1,519,6131,615,080
Total liabilities11,892,71820,735,934
Stockholders' equity:  
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,664,185 shares issued and outstanding as of March 31, 2024, and 12,660,313 shares issued and outstanding as of December 31, 20231,2661,265
Additional paid-in capital28,725,50928,160,745
Retained earnings47,394,68743,258,154
Total Stockholders' Equity76,121,46271,420,164
Total liabilities and stockholders' equity$ 88,014,180$ 92,156,098
IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
 CEO
 WEBSITEiradimed.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES123

iRadimed Corp Frequently Asked Questions


What is the ticker symbol for iRadimed Corp? What does IRMD stand for in stocks?

IRMD is the stock ticker symbol of iRadimed Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iRadimed Corp (IRMD)?

As of Fri Jun 14 2024, market cap of iRadimed Corp is 546.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers. The fair value of iRadimed Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iRadimed Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iRadimed Corp a good stock to buy?

The fair value guage provides a quick view whether IRMD is over valued or under valued. Whether iRadimed Corp is cheap or expensive depends on the assumptions which impact iRadimed Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRMD.

What is iRadimed Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, IRMD's PE ratio (Price to Earnings) is 30.5 and Price to Sales (PS) ratio is 8.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRMD PE ratio will change depending on the future growth rate expectations of investors.